Epidemiologic and Clinical Features of Patients with COVID-19 in Brazil
Overview
Authors
Affiliations
Objective This study describes epidemiological and clinical features of patients with confirmed infection by SARS-CoV-2 diagnosed and treated at Hospital Israelita Albert Einstein , which admitted the first patients with this condition in Brazil. Methods In this retrospective, single-center study, we included all laboratory confirmed COVID-19 cases at Hospital Israelita Albert Einstein , São Paulo, Brazil, from February until March 2020. Demographic, clinical, laboratory and radiological data were analyzed. Results A total of 510 patients with a confirmed diagnosis of COVID-19 were included in this study. Most patients were male (56.9%) with a mean age of 40 years. A history of a close contact with a positive/suspected case was reported by 61.1% of patients and 34.4% had a history of recent international travel. The most common symptoms upon presentation were fever (67.5%), nasal congestion (42.4%), cough (41.6%) and myalgia/arthralgia (36.3%). Chest computed tomography was performed in 78 (15.3%) patients, and 93.6% of those showed abnormal results. Hospitalization was required for 72 (14%) patients and 20 (27.8%) were admitted to the Intensive Care Unit. Regarding clinical treatment, the most often used medicines were intravenous antibiotics (84.7%), chloroquine (45.8%) and oseltamivir (31.9%). Invasive mechanical ventilation was required by 65% of Intensive Care Unit patients. The mean length of stay was 9 days for all patients (22 and 7 days for patients requiring or not intensive care, respectively). Only one patient (1.38%) died during follow-up. Conclusion These results may be relevant for Brazil and other countries with similar characteristics, which are starting to deal with this pandemic.
Nursing terminology for the care of people with respiratory diseases and Covid-19.
Oliveira J, Vasconcelos J, Veras R, Silva V, Franca L, Leite D Rev Esc Enferm USP. 2024; 58:e20230124.
PMID: 38743954 PMC: 11126235. DOI: 10.1590/1980-220X-REEUSP-2023-0124en.
Hao L, Yang X, Chen H, Wei S, Xu B, Zhao Z Microorganisms. 2023; 11(10).
PMID: 37894200 PMC: 10609418. DOI: 10.3390/microorganisms11102542.
Correa T, Midega T, Cordioli R, Barbas C, Rabello Filho R, da Silva B Einstein (Sao Paulo). 2023; 21:eAO0233.
PMID: 37493832 PMC: 10356126. DOI: 10.31744/einstein_journal/2023AO0233.
Petrakis V, Panopoulou M, Rafailidis P, Lemonakis N, Lazaridis G, Terzi I Pathogens. 2023; 12(6).
PMID: 37375470 PMC: 10302285. DOI: 10.3390/pathogens12060780.
Maraia Z, Mazzoni T, Turtora M, Tempera A, Spinosi M, Vagnoni A Antibiotics (Basel). 2023; 12(5).
PMID: 37237815 PMC: 10215319. DOI: 10.3390/antibiotics12050912.